Pfizer Inc. (FRA:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 119.48B |
| Revenue (ttm) | 54.48B |
| Net Income (ttm) | 9.18B |
| Shares Out | n/a |
| EPS (ttm) | 1.62 |
| PE Ratio | 13.02 |
| Forward PE | 8.90 |
| Dividend | 1.55 (7.45%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 1,667 |
| Average Volume | 79,563 |
| Open | 21.06 |
| Previous Close | 20.86 |
| Day's Range | 21.00 - 21.10 |
| 52-Week Range | 18.57 - 27.70 |
| Beta | n/a |
| RSI | 45.29 |
| Earnings Date | Nov 4, 2025 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Pfizer's (PFE) Crizotinib Shows Promise in Uveal Melanoma Trial
Pfizer's (PFE) Crizotinib Shows Promise in Uveal Melanoma Trial
Pfizer (PFE): Promising Data from VERITAC-2 Trial on Breast Cancer Treatment
Pfizer (PFE): Promising Data from VERITAC-2 Trial on Breast Cancer Treatment
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
– Data demonstrated that vepdegestrant maintained patients' quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including p...
Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study
(RTTNews) - Pfizer Inc. (PFE) and Astellas Pharma U.S. Inc. announced final overall survival results from the Phase 3 EMBARK study evaluating XTANDI (enzalutamide), in combination with leuprolide and ...
Pfizer (PFE) Reports Positive PADCEV Trial Results at ESMO 2025
Pfizer (PFE) Reports Positive PADCEV Trial Results at ESMO 2025
XTANDI Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTA...
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
NEW YORK & NORTHBROOK, Ill.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) result...
Pfizer’s BRAFTOVI + MEKTOVI Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) for the treatment of adults with me...
Pfizer's BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for th...
Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients
Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, progression or death in patients suffering from a type of bladder cancer, the comp...
Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients
Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with an aggressive form of bladder cancer.
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer Unprecedented survival result...
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer Unprecedented survival result...
Did Pfizer Overpay For Yet Another Acquisition?
Pfizer enters the obesity drug market with a reasonably valued deal, while valuation remains attractive and technicals show stability. See why PFE stock is a hold.
Pfizer: World-Leading Drug Pipeline Sets Stage For Major Long-Term Potential
Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth potential. See why PFE stock is a buy.
Popular birth control is linked to brain tumors in new study — as over 1,000 women sue Pfizer over health risks
One Louisiana woman, Robin Phillip, said she developed an intracranial meningioma that caused her to lose vision in her left eye and struggle to walk.
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment
The U.K.’s National Institute for Health and Care Excellence (NICE) is recommending a treatment from a firm jointly owned by GSK Plc (NYSE: GSK), Pfizer Inc (NYSE: PFE) and Shionogi Inc . NICE has r...
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades . His promise to cut the cost of Novo Nordisk A/S (NYSE: NVO) blockbuster drug Ozempic from around $1,300...
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to...
Validea Detailed Fundamental Analysis - PFE
Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy of Me...
What's Behind The Slump In Pfizer Stock?
Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped o...
ASSET PLANNING Exits Full Stake in Pfizer Worth $2.7 Million
Key PointsSold entire holding of 109,630 shares; estimated trade value of approximately $2.66 million based on the quarterly average price
QSM Asset Management Buys $6.8 Million of Pfizer Stock as Pharma Giant Lags Market
Key PointsQSM Asset Management added 276,899 shares of Pfizer for an estimated $6.8 million in the third quarter.
America, Inc.
Geopolitical tensions, technological innovation and government policies have been at the forefront of CEO decisions in the banking,defense and pharmaceutical sectors this year. Three industry CEO heav...
Pfizer Strikes $70B Deal with Trump--But Warns China Is Racing Ahead in Biotech War
Pfizer Strikes $70B Deal with Trump--But Warns China Is Racing Ahead in Biotech War